Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy

References

• Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget. 2015;5. doi:10.18632/oncotarget.6113
   Google Scholar
• Yamazaki T, Hannani D, Poirier-Colame V, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21(1):69. doi:10.1038/cdd.2013.7223811849
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017:17(2)2–5.
   Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. doi:10.1038/nri221618097448
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Durham N, Wetzel L, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia. 2015;17(8):661–670. doi:10.1016/j.neo.2015.08.00426408258
   PubMed Web of Science ®Google Scholar
• Green AE, Rose PG. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 2010;363(3):711–723.
   Google Scholar
• Van Der Kraak L, Goel G, Ramanan K, et al. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016;4(1):65. doi:10.1186/s40425-016-0163-827777774
   PubMedGoogle Scholar
• Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343–354. doi:10.1016/j.immuni.2015.11.02426872698
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa100346620525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa110462121639810
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13(1):211. doi:10.1186/s12916-015-0455-826337719
   PubMed Web of Science ®Google Scholar
• Weber J. Review: anti–CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12(7):864–872. doi:10.1634/theoncologist.12-7-86417673617
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325. doi:10.1038/nrd300320305665
   PubMed Web of Science ®Google Scholar
• Nikpoor AR, Tavakkol-Afshari J, Gholizadeh Z, et al. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int J Pharm. 2015;495(1):162–170. doi:10.1016/j.ijpharm.2015.08.04826302860
   PubMedGoogle Scholar
• Nikpoor AR, Tavakkol-Afshari J, Sadri K, et al. Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: in vitro and in vivo studies. Nanomedicine. 2017;13(8):2671–2682. doi:10.1016/j.nano.2017.08.01028847682
   PubMed Web of Science ®Google Scholar
• Ordikhani F, Uehara M, Kasinath V, et al. Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity. JCI Insight. 2018;3(20). doi:10.1172/jci.insight.122700
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:1–14. doi:10.3389/fonc.2018.0008629404275
   PubMed Web of Science ®Google Scholar
• Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of Immune Related Adverse Events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49. doi:10.3389/fphar.2017.0004928228726
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–4293. doi:10.1158/1078-0432.CCR-14-260725977344
   PubMed Web of Science ®Google Scholar
• Zhang N, Song J, Liu Y, et al. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. J Control Release. 2019;306:15–28. doi:10.1016/j.jconrel.2019.05.03631132380
   PubMed Web of Science ®Google Scholar
• Golchin S, Alimohammadi R, Rostami Nejad M, et al. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol. 2019;234(11):19866–19874. doi:10.1002/jcp.2858530941773
   PubMed Web of Science ®Google Scholar
• Wu L, Yun Z, Tagawa T, et al. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther. 2012;11(8):1809–1819. doi:10.1158/1535-7163.MCT-11-101422584123
   PubMed Web of Science ®Google Scholar
• Parra K, Valenzuela P, Lerma N, et al. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017;116(3):324–334. doi:10.1038/bjc.2016.42928056464
   PubMed Web of Science ®Google Scholar
• Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399–411. doi:10.1158/2326-6066.CIR-14-021525678581
   PubMed Web of Science ®Google Scholar
• Nejad EB, Welters MJP, Arens R, et al. Expert opinion on biological therapy the importance of correctly timing cancer immunotherapy. Expert Opin Biol Ther. 2017;17(1):87–103. doi:10.1080/14712598.2017.125638827802061
   PubMed Web of Science ®Google Scholar
• Sutmuller RPM, Van Duivenvoorde LM, Van Elsas A, et al. Synergism of cytotoxic T lymphocyte–associated antigen 4 blockade and depletion of Cd25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194(6):823–832. doi:10.1084/jem.194.6.82311560997
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–1710. doi:10.1084/jem.2013057923897981
   PubMed Web of Science ®Google Scholar